Psoriatic Disease
Denial of methotrexate prescriptions post-Roe yields ‘condemnation’
The June 24 Supreme Court decision to overturn Roe vs. Wade continues to reverberate across all of health care, including rheumatology, dermatology and cancer treatment — and in this instance all three at once.
‘One of the few strategy trials in PsA’: CONTROL sheds light on escalation, biologic use
Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs individually, there are fewer trials examining strategies to treat patients who fail to respond to methotrexate in the first line.
Secukinumab 300 mg viable first-line biologic in patients with psoriatic arthritis
Secukinumab 300 mg is a safe and effective first-line biologic for patients with psoriatic arthritis, according to data from a biologic-naïve population based in the United States.
AI tool may reduce diagnosis time in psoriatic arthritis
A new artificial intelligence tool may improve diagnosis speed in patients with psoriatic arthritis, according to a press release summarizing data from the European Academy of Dermatology and Venereology’s Spring Symposium 2022.
Patients with IMIDs respond well to third COVID-19 vaccine dose
Most patients with immune-mediated inflammatory diseases who had weakened responses to a standard vaccine series for COVID-19 mounted a serological response to a third dose, according to data published in Arthritis and Rheumatology.
Secukinumab minimizes disease activity at 6 months in psoriatic arthritis
Real-world patients with psoriatic arthritis who receive secukinumab for 6 months maintain consistent proportions of minimal disease activity and demonstrate improved patient-reported outcomes, according to data.
‘Very exciting’ data: Bimekizumab superior to placebo in psoriatic arthritis
Patients with psoriatic arthritis treated with bimekizumab demonstrated improvements across joint and skin parameters compared with placebo, according to Phase 3 clinical trial data presented at the EULAR 2022 Congress.
Ustekinumab biosimilar candidate achieves ‘therapeutic equivalence’
AVT04, a biosimilar candidate to ustekinumab developed by Alvotech, met the primary endpoint in a confirmatory clinical study of patients with chronic plaque-type psoriasis, according to a company press.
Psoriatic arthritis trials should seek deeper remission states, end placebo controls
Clinical trials for psoriatic arthritis therapies should place a greater focus on using deeper states of remission as primary and co-primary endpoints, according to speakers at the FDA & American College of Rheumatology Virtual Summit.
United Rheumatology, CreakyJoints launch RA resource during Arthritis Awareness Month
United Rheumatology and CreakyJoints have announced a partnership to launch the Rheumatoid Arthritis Wellness Center, a digital resource that aims to offer support to patients living with RA, according to a press release.